Skip to main content
Clinical Trials/IRCT20210117050055N1
IRCT20210117050055N1Not yet recruitingPhase 3

Effect of synbiotics supplement on fatigue and sleep quality in hemodialysis patients with chronic kidney disease

Sabzevar University of Medical Sciences0 sites60 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 3
Status
Not yet recruiting
Sponsor
Enrollment
60

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to 65 years (—)
Sex
All

Inclusion Criteria

  • A patient with a diagnosis of chronic kidney disease who undergoing hemodialysis for at least 3 months.
  • signing informed consent for participation in the study
  • Patient with arteriovenous fistula or permanent catheter or venous arterial graft
  • The patient undergoing hemodialysis 3 times a week for 4 hours each time
  • Patient with KT / V> 1
  • Do not suffer from hearing and vision disorders
  • No neurological disorders and a history of hospitalization in the psychiatric ward
  • age range of 18 to 65 years

Exclusion Criteria

  • Active infection during the last 30 days
  • Pregnant or lactating mothers
  • Taking antibiotics, prebiotics, probiotics, synbiotics, vitamin supplements or antioxidants during the last 30 days
  • Suffering from autoimmune diseases or connective tissue disorders
  • History of cardiovascular diseases
  • Diabetic foot infection
  • Gastrointestinal diseases (inflammatory bowel disease, ulcerative colitis, Crohn's disease, celiac disease, lactose intolerance or allergy, irritable bowel syndrome)
  • Liver disease (such as hepatitis B, hepatitis C)
  • suffering from various types of malignancies
  • Smoking more than 10 cigarettes per day
  • Participate in other drug interventions
  • hemoglobin less than 8 mg/dl
  • PSQI score less than 6 (good sleep quality)
  • acquisition of CFS score less than 18

Investigators

Sponsor
Sabzevar University of Medical Sciences

Similar Trials